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Abstract
Background: Orbital infiltration in patients with multiple myeloma is a rare condition, with less
than 50 cases reported in the medical literature. Most patients undergo conservative treatment
because multiple myeloma is a disseminated systemic disease.
Case presentation: A 43-year-old male subject with multiple myeloma and long-term survival
presented with orbital involvement. The subject lacked the typical features and poor prognostic
factors associated with multiple myeloma, such as renal failure, hypercalcemia, and paraprotein in
the serum and urine. The orbital computed tomographic scan revealed the tumor encasing the
optic nerve, but without prominent bony destruction. Therefore, a frontal skull craniotomy with
an epidural entrance to the orbital space was performed, to completely extirpate the orbital mass.
The surgical procedure was followed by moderate-dose radiation therapy. After 32 months of
follow-up care, the subject is doing well with excellent local control.
Conclusion: Although the effectiveness and applicability of this approach remains to be
determined, this case report demonstrates that accurate and early detection combined with local
surgical treatment and appropriate radio/chemotherapy, can be applied to effectively extend an
orbital multiple myeloma patient's life.
Background
Multiple myeloma presents as a systemic, disseminated
disease and represents an uncontrolled proliferation of
plasma cells with the overproduction of proteins belong-
ing to the immunoglobulin family, and accounts for 1%
to 2% of all cancers [1]. The median age at diagnosis is the
sixth decade, and there is a progressive increase in inci-
dence with age, reaching a maximum in the seventh dec-
ade of life. Multiple myeloma is characterized by the
neoplastic proliferation of a single clone of plasma cells,
leading to enhanced levels of paraprotein in serum and/or
urine. The plasma cells proliferate in the bone marrow
and frequently invade adjacent bone, causing skeletal
destruction that results in bone pain and pathological
fractures. Bone marrow involvement may be focal rather
than diffuse, which requires repeated bone marrow exam-
inations in order to obtain an accurate diagnosis [1].
A report from the International Myeloma Working Group
in 2003 [2], indicates that urine contains paraprotein in
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patients with multiple myeloma have paraprotein in the
serum or urine at the time of diagnosis. However, a
minority of patients with non-secretory myeloma have no
monoclonal protein. Only 3% of patients with sympto-
matic multiple myeloma are found to have no parapro-
tein in their plasma cells [3]. Treatment for non-secretory
myeloma is similar to that for multiple myeloma, and
both share a similar response to therapy and survival rate.
Plasma cell myeloma, or orbital myelomatosis is a rare
and diverse condition, even among patients with known
multiple myeloma [4]. The differential diagnosis of
orbital tumors includes metastatic carcinoma, malignant
lymphoma, optic pseudotumor, lacrimal gland tumors, as
well as plasma cell tumors. It is estimated that fewer than
50 cases of orbital myelomatosis have been reported in
the medical literature [5]. A plasmacytoma of the orbit
presents with non-specific symptoms, including propto-
sis, a change in visual acuity, displacement of the orbit,
and diplopia. In fact, 80% of patients with orbital multi-
ple myeloma present with proptosis, although visual
impairment, varying from minor defects to complete
blindness, are also often observed [5]. The tumors typi-
cally arise from the bone and extend into the soft tissue.
Accurate diagnosis of an orbital tumor arising from mye-
loma is particularly challenging in patients who do not
have a history of multiple myeloma.
In the current report, we present a patient with multiple
myeloma who had an unusual presentation, and has
experienced an extended survival after undergoing a fron-
tal skull craniotomy followed by moderate-dose radio-
therapy.
Case presentation
The subject examined herein was a 43-year-old male fac-
tory worker. Seven years before this study was initiated, he
had a motorcycle accident and experienced pain in the left
hip for which he was referred to our Emergency Depart-
ment (ED). A left hip intertrochanteric fracture was sus-
pected based on radiologic observations. A curettage with
internal fixation of the left femur was performed, and the
pathologic report noted lobules of mature plasma cells in
the bone and soft tissue. Further assessment of the condi-
tion was carried out post-surgery. A standard skull X-ray
series revealed typical "punched out" osteolytic lesions.
Systemic disease was considered, however, bone marrow
analysis was normal and no abnormal monoclonal gam-
mopathy was detected by serum immunoelectrophoresis.
Blood analysis, including calcium level and complete
blood count were normal. In addition, no serum parapro-
tein or urinary free light chains were detected. Therefore,
non-secretory multiple myeloma was proposed and the
patient received radiotherapy (5040 cGy in 28 fractions),
via a linear accelerator to the site of the proximal femoral
lesion after the surgical incision had properly healed.
Three months after the completion of radiotherapy, the
patient reported significant back pain. Whole bone scin-
tigraphy showed an increased uptake over the thoracic
spine, and a magnetic resonance imaging (MRI) study of
the spine revealed multiple areas of bony destruction
involving T2-T4. A laminectomy of the thoracic spine with
resection of the spinal tumor was done performed (3.5
months after completion of radiotherapy). The pathologic
report was consistent with a plasma cell tumor and non-
secretory multiple myeloma (Fig. 1). Post-surgery, the
subject underwent radiotherapy to the thoracic spine
(4500 cGy in 25 fractions), followed by oral chemother-
apy with mephalan (12 mg/day) and prednisolone (100
mg/day), 4 days/month.
Approximately 2.5 years ago, the patient developed pro-
gressive proptosis and a limitation of gaze. An ophthal-
mologic examination at that time revealed a visual acuity
of 20/40 in the right eye and 20/200 in the left eye. The
left eye was noted to protrude 5 mm more anteriorly than
the right eye. A computerized tomographic (CT) scan of
the orbit revealed a left intraorbital mass lesion occupying
the upper-outer quadrant, compressing the superior rectal
muscle and encasing the optic nerve, but without promi-
nent bony destruction (Fig. 2, 3).
In order to expeditiously release the nerve-compression, a
left frontal skull craniotomy to the midline was per-
formed, prior to an epidural retraction of the left frontal
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Light microscopy image of formalin-fixed tissue dem-
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canal was reached. Some tumor-like tissue was identified
on the orbital roof. After removing the tumor-like tissue,
unroofing of the orbit was performed. Histopathological
examination of the tissue revealed bone and soft tissue
with infiltrating plasma cells containing round, eccentric,
hyperchromatic nuclei, consistent with a diagnosis of
plasma cell tumor. At the time of surgery, the tumor was
found to have invaded the orbital cavity, encased the optic
nerve, and also infiltrated superiorly compressing the
levator and superior rectus muscles. Further unroofing of
the orbit was done to excise residual non-visible tumor
ensuring total removal. Two titanium mesh patches were
used to control orbital pressure. After surgery, the subject's
left eye exhibited no significant exophlathesis and he
reported a slightly blurred vision.
At follow-up one month after surgery, examination
revealed markedly decreased proptosis of the eye and the
subject was referred to the radiation oncology department
for additional treatment The patient underwent radiother-
apy to the primary orbit tumor bed, with a dose of 3960
cGy in 22 fractions. As the patient experienced did not tol-
erate the prior medical treatment, Zometa® (zoledronic
acid; Novartis), 4 mg/month was administered during the
course of radiation therapy to prevent disease progression.
The subject was followed every 2 to 4 month with exami-
nations and visual acuity checks, and bone scans every 6
months. At follow-up examination 32 months after fron-
tal skull craniotomy followed by moderate-dose radio-
therapy, his visual acuity was 20/50 in the left eye and he
had no other complaints. CT scan at that time showed
post-surgery changes in the retro-orbital area and no
abnormal mass tissue was noticed.
Discussion
Care should be taken in the diagnosis of orbital multiple
myeloma, as it has been demonstrated that orbital plas-
macytoma may mimic other orbital tumors such as men-
ingioma, melanoma, and orbital carcinoma under
angiography [6]. Optic nerve sheath meningiomas
(ONSMs) account for 1-2% of all meningiomas. The most
frequent presenting symptom of ONSM is painless loss of
visual acuity. The ONSM surrounds the optical nerve and
the caliber of optical nerve is attenuated within the sur-
rounding tumor. This is in contrast to optical nerve glio-
mas, where the optical nerve itself is expanded [7].
Mitoses, architectural disruption, calcification, and MIB-1
staining are also described. The distribution of ocular
melanoma are 80% in the choroid, 10-15% in the ciliary
body, and <10% in the iris. The pathologic findings
include spindle cells (30%), epithelioid cells (5%), and
mixed cells (65%) (contains spindle and epithelioid cells)
[8]. Vascular lesions account for 5%-20% of orbital
masses, and hemangioma and lymphangioma are the
most common vascular lesions in the orbit. The vascular
Axial view of the orbital computerized tomographic scan showing the tumor encasing the optic nerveFigure 2
Axial view of the orbital computerized tomographic 
scan showing the tumor encasing the optic nerve. 
Prominent bony destruction could not be observed.
Coronal view of the orbital computerized tomographic scan sh wing left intra-orbital mass lesion, occupying the upper-outer quadra  and c mpressing the superi r rectus muscleFigu e 3
Coronal view of the orbital computerized tomo-
graphic scan showing left intra-orbital mass lesion, 
occupying the upper-outer quadrant and compress-
ing the superior rectus muscle.Page 3 of 5
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distinguish hemangioma from these other lesions.
Hemangiomas are vascular and multilobular at gross
examination. Histologically, the tumor growth appears
infiltrative and may involve adjacent orbital structures. In
the early proliferative phase, the lesion is composed of
densely packed, plump, hyperplastic endothelial cells that
form clusters or lobules [9].
In the current case study examined a subject with orbital
multiple myeloma. Malignant carcinoma was excluded
because it is usually accompanied by prominent bony
destruction and is characterized by an extended area of
invasion. Neither the physical exam or laboratory findings
suggested the presence of malignant lymphoma. The
occurrence of an inflammatory pseudotumor was also
unlikely, as no episodes of erythema involving the eyelid
had occurred in this patient. The clinical findings indi-
cated a rare case, as plasma cell tumors with orbital
involvement are not often reported, even among patients
with known multiple myeloma. Reports suggest that
orbital involvement in patients with multiple myeloma
may be a first sign of insufficient treatment or the first sign
of systemic disease [10,11] In addition, fine needle aspira-
tion of has been shown to play a role in the diagnosis
when extramedullary involvement is suspected [11].
Because multiple myeloma is a systemic, disseminated
disease, chemotherapy is the preferred treatment modal-
ity. Local, aggressive treatments such as surgery are gener-
ally not used; however, in the subject examined herein,
proptosis and limitation of gaze occurred over a short
time period and chemotherapy was not suitable for local
control, especially in the orbit area. External beam radia-
tion therapy can achieve superior local therapeutic results
when used at a relatively high dose of 5000-6000 cGy
[12]. However, the dose of radiation, its method of deliv-
ery, and possible irradiation of surrounding normal tis-
sues may largely depend on the tumor mass present at the
time of treatment. If radiotherapy is the only available
choice because the tumor is located in the intra-orbital
and retrobulbar regions, protecting the retinas and lenses
of both eyes is technically challenging.
In our case, the subject survived for more than 84 months
since diagnosis, which is nearly twice the mean survival
time [13]. Alexanian [14] and Cherng et al. [15] revealed
that several clinical criteria influence a patient's duration
of remission and survival time: a hemoglobin count of
<8.5 g/100 ml, elevation of the ionized calcium level, an
IgG peak of >7 g/100 ml, and hypoalbuminemia were all
associated with shorter survival. Our subject never exhib-
ited anemia, hypercalcemia, or renal insufficiency, and his
performance status was excellent. Therefore, we decided
to employ an unusual therapy, i.e., surgical removal, that
did not induce prominent complications. We completely
removed the gross optic tumor and applied radiotherapy
post-surgery using a moderate radiation dose to better
control residual microscopic tumor development. In a
recent report, Gönül et al. [16] used right orbitozygomatic
craniotomy to successfully remove a mass lesion in a 60-
year-old subject diagnosed with orbital multiple mye-
loma.
The surgical approach that we undertook was distinct
from that followed by most surgeons [17,18]. We chose a
frontal skull craniotomy with an epidural approach to the
orbital space because the intraorbital mass lesion occu-
pied the upper-outer quadrant, compressing the superior
rectus muscle, and encasing the optic nerve. Although we
realized that the 2nd, 3rd, 4th, and 6th cranial nerves could
be injured by an orbital approach, the surgical procedure
allowed removal of the majority of the tumor, which sub-
stantially increased the control rate of the adjuvant radio-
therapy.
Numerous reports describe invasion of the orbit by multi-
ple myeloma, as demonstrated by CT scan [5,18-20]. Most
of these cases had large soft tissue masses arising from
within the bone, causing bony expansion and destruction
that could not be ameliorated by surgery. In addition, the
patients exhibited a number of poor prognostic factors,
such as high serum or urine paraprotein, low hemo-
globin, or multiple bony lesions, and thus palliative radi-
otherapy was chosen to relieve nerve compression. In
some reports, a palliative radiotherapy dose (i.e., a total
dose <3000 cGy) was chosen[17,21]; however, the dose
was intended for palliative treatment and the radiation
field using this dose was designed to encompass the
whole bone, if possible. The daily dose should exceed 200
cGy to achieve a better radiation effect. If we had initially
used a total dose <3000 cGy, the optic tumor may have
redeveloped after a period of time. Also, a fractional dose
>200 cGy per day would injure optic structures, such as
the optic nerve, lens, or retina. In our subject, although
myeloma was diagnosed in the left femur and thoracic
spine, symptom-free survival has extended to 32 months
after completion of the radiotherapy, which is signifi-
cantly longer than the reported median survival [13].
Although the effectiveness and applicability of this
approach remains to be determined though the evalua-
tion of its application in additional cases of orbital multi-
ple myeloma, this case report demonstrates that accurate
and early detection, currently facilitated by magnetic reso-
nance imaging [22], combined with local surgical treat-
ment and appropriate radio/chemotherapy, can be
applied to effectively extend an orbital multiple myeloma
patient's life.Page 4 of 5
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